HC Wainwright Has Pessimistic Outlook of ORIC Q2 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – HC Wainwright lowered their Q2 2025 EPS estimates for shares of ORIC Pharmaceuticals in a research note issued on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.55) per share for the quarter, down from their prior estimate of ($0.54). HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01).

A number of other equities research analysts have also issued reports on the stock. Wells Fargo & Company started coverage on shares of ORIC Pharmaceuticals in a report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $18.29.

ORIC Pharmaceuticals Stock Down 7.6 %

Shares of ORIC opened at $10.04 on Thursday. ORIC Pharmaceuticals has a 52-week low of $6.33 and a 52-week high of $16.65. The stock has a fifty day simple moving average of $9.01 and a two-hundred day simple moving average of $9.46. The company has a market capitalization of $708.52 million, a PE ratio of -5.58 and a beta of 1.18.

Institutional Trading of ORIC Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in shares of ORIC Pharmaceuticals by 297.4% in the second quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock valued at $5,531,000 after purchasing an additional 585,447 shares during the period. Dimensional Fund Advisors LP lifted its holdings in ORIC Pharmaceuticals by 190.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock worth $3,299,000 after buying an additional 305,860 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in ORIC Pharmaceuticals by 152.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock valued at $4,205,000 after buying an additional 247,863 shares during the period. Franklin Resources Inc. grew its stake in shares of ORIC Pharmaceuticals by 26.1% in the third quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after acquiring an additional 196,804 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of ORIC Pharmaceuticals during the third quarter worth $1,316,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ORIC Pharmaceuticals

In related news, CEO Jacob Chacko sold 24,660 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the sale, the chief executive officer now owns 778,648 shares in the company, valued at approximately $6,447,205.44. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,286.28. Following the transaction, the chief financial officer now directly owns 106,764 shares in the company, valued at approximately $884,005.92. The trade was a 7.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,361 shares of company stock worth $350,749 over the last three months. Insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.